Department of Epidemiology and Biostatistics School of Public Health, Imperial College London London United Kingdom.
Division of Cardiovascular Medicine Hospital of the University of Pennsylvania Philadelphia PA USA.
J Am Heart Assoc. 2024 Aug 20;13(16):e035008. doi: 10.1161/JAHA.124.035008. Epub 2024 Aug 9.
Circulating plasma proteins are clinically useful biomarkers for stroke risk. We examined the causal links between plasma proteins and stroke risk in individuals of South Asian ancestry.
We applied proteome-wide Mendelian randomization and colocalization approaches to understand causality of 2922 plasma proteins on stroke risk in individuals of South Asian ancestry. We obtained genetic instruments (proxies) for plasma proteins from the UK Biobank (N=920). Genome-wide association studies summary data for strokes (N≤11 312) were sourced from GIGASTROKE consortium. Our primary approach involved the Wald ratio or inverse-variance-weighted methods, with statistical significance set at false discovery rate <0.1. Additionally, a Bayesian colocalization approach assessed shared causal variants among proteome, transcriptome, and stroke phenotypes to minimize bias from linkage disequilibrium. We found evidence of a potential causal effect of plasma GP6 (glycoprotein VI) levels on cardioembolic stroke (odds ratio [OR]=2.53 [95% CI, 1.59-4.03]; =9.2×10, false discovery rate=0.059). Generalized Mendelian randomization accounting for correlated single nucleotide polymorphisms (SNPs), with the value threshold at <5×10 and clumped at =0.3, showed consistent direction of effect of GP6 on cardioembolic stroke (OR=2.21 [95% CI, 1.46-3.33]; =1.6×10). Colocalization analysis indicated that plasma GP6 levels colocalize with cardioembolic stroke (posterior probability=91.4%). Multitrait colocalization combining transcriptome, proteome, and cardioembolic stroke showed moderate to strong evidence that these 2 traits colocalize with expression in the coronary artery and brain tissues (multitrait posterior probability>50%). The potential causal effect of GP6 on cardioembolic stroke was not significant in European populations (OR=1.08 [95% CI, 0.93-1.26]; =0.29).
Our joint Mendelian randomization and colocalization analyses suggest that genetically predicted GP6 is potentially causally associated with cardioembolic stroke risk in individuals of South Asian ancestry. As genetic data on individuals of South Asian ancestry increase, future Mendelian randomization studies with larger sample size for plasma GP6 levels should be implemented to further validate our findings. Additionally, clinical studies will be necessary to verify GP6 as a therapeutic target for cardioembolic stroke in South Asians.
循环血浆蛋白是中风风险的临床有用的生物标志物。我们研究了南亚血统个体中血浆蛋白与中风风险之间的因果关系。
我们应用蛋白质组全基因组 Mendelian 随机化和共定位方法来了解南亚血统个体中 2922 种血浆蛋白对中风风险的因果关系。我们从英国生物库(N=920)获得了血浆蛋白的遗传工具(代表)。中风的全基因组关联研究汇总数据(N≤11312)来自 GIGASTROKE 联盟。我们的主要方法包括 Wald 比或逆方差加权方法,统计显著性设置为假发现率<0.1。此外,贝叶斯共定位方法评估了蛋白质组、转录组和中风表型之间的共同因果变异,以最大限度地减少连锁不平衡的偏差。我们发现血浆 GP6(糖蛋白 VI)水平对心源性栓塞性中风的潜在因果作用的证据(比值比[OR]=2.53[95%CI,1.59-4.03];=9.2×10,假发现率=0.059)。考虑到相关单核苷酸多态性(SNP)的广义 Mendelian 随机化, 值阈值为<5×10 且聚类为=0.3,显示 GP6 对心源性栓塞性中风的影响方向一致(OR=2.21[95%CI,1.46-3.33];=1.6×10)。共定位分析表明,血浆 GP6 水平与心源性栓塞性中风共定位(后验概率=91.4%)。结合转录组、蛋白质组和心源性栓塞性中风的多性状共定位显示,这些 2 个性状与冠状动脉和脑组织中的 表达共定位的证据为中等至强(多性状后验概率>50%)。在欧洲人群中,GP6 对心源性栓塞性中风的潜在因果作用不显著(OR=1.08[95%CI,0.93-1.26];=0.29)。
我们的联合 Mendelian 随机化和共定位分析表明,遗传预测的 GP6 可能与南亚血统个体的心源性栓塞性中风风险有因果关系。随着南亚血统个体的遗传数据增加,应该实施具有更大 GP6 血浆水平样本量的未来 Mendelian 随机化研究,以进一步验证我们的发现。此外,需要进行临床研究以验证 GP6 作为南亚人心源性栓塞性中风的治疗靶点。